0.49%
10.81%
-11.26%
-27.05%
-45.91%
-57.91%
-48.49%
AI Spotlight on ARMP
Company Description
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.It develops its products using its proprietary bacteriophage-based technology.The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents.The company is headquartered in Marina del Rey, California.
Market Data
| Last Price | 2.05 |
| Change Percentage | 0.49% |
| Open | 2.05 |
| Previous Close | 2.04 |
| Market Cap ( Millions) | 74 |
| Volume | 3615 |
| Year High | 4.48 |
| Year Low | 1.8 |
| M A 50 | 2.12 |
| M A 200 | 2.46 |
Financial Ratios
| FCF Yield | -56.74% |
| Dividend Yield | 0.00% |
| ROE | 89.12% |
| Debt / Equity | -275.29% |
| Net Debt / EBIDTA | -394.65% |
| Price To Book | -1.46 |
| Price Earnings Ratio | -1.79 |
| Price To FCF | -1.76 |
| Price To sales | 29.74 |
| EV / EBITDA | -6.32 |
News
- Dec -19 - Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
- Nov -19 - Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
- Nov -13 - Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates
- Nov -13 - Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
- Nov -12 - Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
- Oct -30 - Armata Pharmaceuticals Announces Structural Biology Publication
- Sep -12 - Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock?
- Sep -05 - Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- Aug -26 - Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium
- Aug -15 - Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer
- Aug -13 - Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update
- Jul -30 - Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
- Jul -11 - Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
- Jul -10 - Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024
- May -07 - Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update
- Mar -21 - Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
- Mar -04 - Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
- Feb -21 - Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit
- Nov -14 - Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
- Oct -30 - Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Pathogen-specific Bacteriophage Therapeutics
Expected Growth : 10.5 %
What the company do ?
Pathogen-specific Bacteriophage Therapeutics from Armata Pharmaceuticals, Inc. uses targeted viruses to selectively kill antibiotic-resistant bacteria, offering a novel approach to combat antimicrobial resistance.
Why we expect these perspectives ?
Armata Pharmaceuticals' Pathogen-specific Bacteriophage Therapeutics growth is driven by increasing antibiotic resistance, rising demand for targeted therapies, and growing awareness of phage therapy's potential to combat multi-drug resistant infections. Additionally, partnerships with leading research institutions and government agencies, as well as expanding product pipelines, contribute to the 10.5% growth rate.
Armata Pharmaceuticals, Inc. Products
| Product Range | What is it ? |
|---|---|
| AP-PA02 | A bacteriophage-based therapeutic candidate for the treatment of Pseudomonas aeruginosa infections |
| AP-SA01 | A bacteriophage-based therapeutic candidate for the treatment of Staphylococcus aureus infections |
| AP-PA01 | A bacteriophage-based therapeutic candidate for the treatment of Pseudomonas aeruginosa infections |
| AP-EC01 | A bacteriophage-based therapeutic candidate for the treatment of Escherichia coli infections |
Armata Pharmaceuticals, Inc.'s Porter Forces
Threat Of Substitutes
Armata Pharmaceuticals, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies in the market.
Bargaining Power Of Customers
Armata Pharmaceuticals, Inc. has a low bargaining power of customers due to the lack of concentration of buyers in the market.
Bargaining Power Of Suppliers
Armata Pharmaceuticals, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers in the market.
Threat Of New Entrants
Armata Pharmaceuticals, Inc. has a high threat of new entrants due to the attractiveness of the market and the ease of entry.
Intensity Of Rivalry
Armata Pharmaceuticals, Inc. operates in a highly competitive market with many established players, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 153.69% |
| Debt Cost | 3.95% |
| Equity Weight | -53.69% |
| Equity Cost | 8.10% |
| WACC | 1.72% |
| Leverage | -286.26% |
Armata Pharmaceuticals, Inc. : Quality Control
Armata Pharmaceuticals, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CPRX | Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, … |
| AKBA | Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral … |
| MDXG | MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts … |
| LQDA | Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of … |
| URGN | UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Catalyst Pharmaceuticals
A-Score
1-Year Total Return ->
🥈
Akebia Therapeutics
A-Score
1-Year Total Return ->
🥉
MiMedx
A-Score
1-Year Total Return ->
4
Armata Pharmaceuticals
A-Score
1-Year Total Return ->
5
UroGen Pharma
A-Score
1-Year Total Return ->
6
